Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Portrazza Generic Name & Formulations
Legal Class
Rx
General Description
Necitumumab 800mg/50mL; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Human epidermal growth factor receptor (EGFR) inhibitor.
How Supplied
Single-use vial—1
Manufacturer
Generic Availability
NO
Portrazza Indications
Indications
In combination with gemcitabine and cisplatin, for first-line treatment of metastatic squamous non-small cell lung cancer.
Limitations of Use
Not for treatment of non-squamous non-small cell lung cancer.
Portrazza Dosage and Administration
Adult
Give by IV infusion over 60 mins prior to gemcitabine and cisplatin infusion. 800mg on Days 1 and 8 of each 3-week cycle; continue until disease progression or unacceptable toxicity. May premedicate with diphenhydramine HCl (or equivalent) if previously experienced a Grade 1/2 infusion-related reaction. Dose modifications: see full labeling.
Children
Not established.
Portrazza Contraindications
Not Applicable
Portrazza Boxed Warnings
Boxed Warning
Cardiopulmonary arrest. Hypomagnesemia.
Portrazza Warnings/Precautions
Warnings/Precautions
Risk of cardiopulmonary arrest and/or sudden death, hypomagnesemia. History of coronary artery disease, CHF, or arrhythmias. Monitor serum electrolytes (eg, magnesium, potassium, calcium) prior to each infusion during therapy and for at least 8 weeks after last dose; withhold for Grade 3/4 electrolyte abnormalities and may resume once improved to Grade ≤2. Replete electrolytes as medically appropriate. Discontinue if serious or life-threatening venous/arterial thromboembolic events or infusion-related reactions occur. Discontinue if Grade 4 skin reactions or Grade 3 skin induration/fibrosis occurs. Limit sun exposure. Embryo-fetal toxicity. Pregnancy; avoid. Use effective contraception during treatment and for 3 months after last dose. Nursing mothers: not recommended (during therapy and for 3 months after last dose).
Portrazza Pharmacokinetics
See Literature
Portrazza Interactions
Not Applicable
Portrazza Adverse Reactions
Adverse Reactions
Rash, dermatitis acneiform, vomiting, diarrhea, thromboembolic events, hypomagnesemia, hypocalcemia, hypokalemia; cardiopulmonary arrest, dermatologic toxicities, infusion reactions.
Portrazza Clinical Trials
See Literature
Portrazza Note
Not Applicable
Portrazza Patient Counseling
See Literature
